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Objective: During the development of disease-modifying osteoarthritis (OA) drugs, rat models of OA are
frequently used for a ﬁrst assessment of in vivo efﬁcacy. The most efﬁcacious compound in the rat model
may then be tested in a larger animal model before entering human trials. The aim of this study was to
describe a histologic scoring system for use in different models of OA in rats that allows standardization
and comparison of results obtained by different investigators.
Methods: The experience of the authors with current scoring systems and the range of lesions observed
in rat and human OA studies were considered in recommending this common paradigm for rat histologic
scoring. Considerations were made for reproducibility and ease of use for new scorers. Additional scoring
paradigms may be employed to further identify speciﬁc effects of some disease-modifying drugs.
Results: Although the described scoring system is more complex than the modiﬁed Mankin scores, which
are recommended for some other species, the reliability study showed that it is easily understood and
can be reproducibly used, even by inexperienced scorers.
Conclusions: The scoring paradigm described here has been found to be sufﬁciently sensitive to
discriminate between treatments and to have high reproducibility. Therefore we recommend its use for
evaluation of different rat OA models as well as assessment of disease-modifying effects of treatments in
these models.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Spontaneous osteoarthritis (OA) is extremely uncommon in rats
of all strains, although minor foci of articular cartilage
degeneration have been observed1,2. The most commonly used rat
OA model is the surgically-induced medial meniscal tear (MMT)
model3e5, followed by anterior cruciate ligament transection
(ACLT) alone6e8 or in combination with (partial) medial menis-
cectomy (ACLTþ pMMx)9,10 (Gerwin and Gliem, unpublished data).
Few publications describe partial meniscectomy alone8,11. The




s Research Society International. Pimpact exercise of rats is used to increase severity and/or
frequency of OA6,10,11, while moderate-impact exercise appears to
decrease OA severity12. Intra-articular iodoacetate injection13e16 is
also frequently performed, but it is considered to be a model of
cartilage damage, aggressive subchondral bone lesions, inﬂam-
mation and joint pain caused by chemically-induced chondrocyte
death, rather than a model of OA. Models of surgically-created
partial and full-thickness cartilage defects in rats are used mainly
for gene therapy, stem cell transplantation, artiﬁcial cartilage
implantation and local growth factor treatment studies17e20.
Ovariectomy in rats has been done to model postmenopausal OA in
humans21, but the observed cartilage lesions are extremely mild
and do not progress sufﬁciently to allow for disease modiﬁcation
studies (S. Glasson, unpublished observations). Transgenic rat
models of OA are not yet available, but OA-like pathology was
described for mutant strains of rats e.g., homozygous dwarf dw/dw
rats, which have reduced growth hormone (GH) levels22. The
available rat models are listed in Table I.ublished by Elsevier Ltd. All rights reserved.
Table I
Models of OA in the rat
Model Publications Comments
Spontaneous OA models  Gyarmati et al.1
 Smale et al.2
No model exists as spontaneous OA has not been reported




 Janusz et al.4
 Moore et al.5
 Fernihough et al.24
 Wancket et al.32
 Bove et al.25
 Flannery et al.29
 Baragi et al.23
 Glasson et al.33
DMOAD activity shown for
 broad-spectrum MMP inhibitors4,
 selective MMP-13 inhibitors23,
 selective ADAMTS inhibitors33,
 FGF-18, which indicates that cartilage repair strategies
can be evaluated in this model5.
ACLT  Williams et al.6
 Stoop et al.7
 Karahan et al.8
 Galois et al.12
 Hayami et al.26
 Jean et al.34
DMOAD activity shown for
 bisphosphonate Alendronate; protects cartilage and bone26,
 COX-2 inhibitor parecoxib; inhibits cartilage degeneration34.
ACLTþ pMMx  Hayami et al.9
 Appleton et al.10
 Yorimitsu et al.30
 Gerwin and Gliem,
unpublished results
pMMx  Karahan et al.8
 Lozoya and Flores11
Ovariectomy
Ovariectomy as a model of postmenopausal OA  Hoeg-Andersen et al.21 Cartilage lesions are extremely mild and do not progress sufﬁciently
to allow for disease modiﬁcation studies.
Enzymatic/chemically-induced OA
Intra-articular iodoacetate injection  Kalbhen13
 Guingamp et al.14
 Guzman et al.15
 Janusz et al.16
Frequently used as model of joint pain. Morphologic changes in
cartilage do not resemble OA lesions.
Aggressive subchondral bone lesions form the basis for
macroscopic evaluation.
Intra-articular papain injection  Lin et al.35
Intra-articular collagenase injection  Yeh et al.36
Denervation model
Intra-articular injection of immunotoxin  Salo et al.37
Impact models
None in routine use
Genetic models
Transgenic or knockout models None available
Mutant strains dw/dw rats  Ekenstedt et al.22 Very reproducible, but mild, OA-like lesions.
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Rat MMT model of OA
Unilateral MMT in mature rats results in rapidly progressive
cartilage degenerative changes characterized by chondrocyte and
proteoglycan (PG) loss, ﬁbrillation, osteophyte formation, and
chondrocyte cloning3,4. Cartilage degenerative changes develop
progressively and, by 3e6 weeks post-surgery, may be focally
severe on the outer 1/3 of the medial tibia (adjacent to the syno-
vium) with lesions of lesser severity in the middle and inner 1/3
(Fig. 1). Osteophytes progressively increase in size. The model
results in total cartilage loss (to eburnated bone) in 12 months in
the medial tibia of virtually all rats. Zonal analysis can detect the
effects of different types of treatment because the pathogenesis of
lesions differs in the three zones of the medial tibia: the outer zone
(zone 1-adjacent to the synovium at the medial edge of joint) is
subjected to more mechanical forces, while the inner zones (zone
2-central, zone 3-adjacent to the central cruciate ligaments) incur
less mechanical forces. Femoral lesions may be highly variable as
a result of iatrogenic injury to the femur during surgery.The MMT model offers the opportunity to evaluate not only
chondroprotective effects of agents4,23 and cartilage repair strate-
gies5, but also bone preserving activities since this model exhibits
early subchondral resorptive and later sclerotic bone changes.
Effects of treatments on repair of the medial capsule and transected
meniscal collateral ligament (MCL) as well as effects on synovium
can be studied if joints are left intact for microscopic evaluation.
Thickening of the medial joint capsule was, for example, observed
after treatment with broad-spectrum matrix metalloproteinase
(MMP) inhibitors at 3e13 weeks following MMT induction
(S. Glasson et al., unpublished results), probably due to inhibition of
matrix degradation during the repair process. Identiﬁcation of such
an increase in capsule thickness is important because capsular
ﬁbroplasia may contribute to joint stabilization, serving as an
additional mechanism to inﬂuence cartilage degradation. More
recently, MMT was identiﬁed as a model of joint pain, measured as
reduction in paw withdrawal thresholds and reduced weight-
bearing of the operated leg24. Responsiveness to a cyclooxygenase
(COX)-2 inhibitor and a neuropathic pain medication suggests that
MMT can also be used as a model for the development of phar-
macologic interventions for symptomatic treatment of OA25.
Fig. 1. A. Schematic drawing of the rat knee joint after ACLT surgery (image was taken from reference7). Areas surrounded by dotted lines are central locations of cartilage
degeneration in the medial tibia plateau (MTP) and medial femoral condyle (MFC). Black, open, and striped areas represent peripheral cartilage areas of chondrocyte death in the
lateral and medial femur. B. Histological section of the MTP and the MFC of a rat with OA lesions 3 weeks after MMT surgery. For evaluation, the tibial plateau is divided into three
zones of equal width using an ocular micrometer or a ruler on a photograph, with zone 1 (Z1) on the outside (medial edge of joint) and zone 3 (Z3) on the inside (adjacent to the
central cruciate ligaments). Zones are delineated by red lines. The projected cartilage surface and the tidemark are delineated by green tracing.
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Unilateral surgical ACLTþ pMMx in mature rats also leads to
the development of progressive cartilage degeneration, but
progression is slower than in the MMT model, with focal cartilage
erosion developing at 4e12 weeks post-surgery (vs 3e6 weeks in
the MMT model)9,10 (Gerwin and Gliem, unpublished results).
Similar to the MMT model, cartilage lesions develop mainly in
the outer 1/3 of the medial tibia, however, in the ACLTþ pMMx
model, lesions also develop in the medial femur. Osteophytes are
detected in 50e75% of the animals, at the outer margins of the
medial tibial plateau (MTP), beginning at 4e6 weeks post-surgery
(Gerwin and Gliem, unpublished results)9. Total cartilage loss can
occur, but only at very late time points after surgery (10e12
weeks)9,10 (Gliem and Gerwin, unpublished results). Subchondral
bone sclerosis is always observed in this model. Progression time
of cartilage degeneration is shorter if the MCL is transected9 than
if it is left intact10 (Gerwin and Gliem, unpublished results).
Furthermore, severity of cartilage degeneration increases
proportionally to the amount of the medial meniscus that is
removed.
ACLT alone leads to less severe cartilage degeneration and this
develops later and progresses more slowly than in the
ACLTþ pMMx model when the two models are studied side-by-
side7,9 (Gerwin and Gliem, unpublished results). Focal cartilage
ﬁbrillation is observed, but not as reliably as in the ACLTþ pMMx
model, and no severe cartilage loss is detected after ACLT alone in
animals followed up to 12 weeks after surgery. Osteophytes are
small or absent. Interestingly, replacement of articular cartilage by
ﬁbrocartilage, most frequently detected in the lateral femoral
condyle, is a feature of the ACLT model but not the ACLTþ pMMx
model7,9 (Gerwin and Gliem, unpublished results).
To our knowledge, the three models have not been compared
side-by-side by a single surgeon using the same histological
assessment scheme. However, published data and our own
unpublished results suggest that the ACLTþ pMMx and the ACLT
model, have a slower progression of OA, and result in less severe
disease, than the MMT model, particularly if the MCL is not trans-
ected. Therefore, the threshold for detecting protective effects of
therapeutic interventions is expected to be lower in the ACLT and
ACLTþ pMMx models than in the MMT model. However, cartilage
and bone protective effects in the ACLT model have been published
so far for only one therapeutic agent, that being the bone resorption
inhibitor Alendronate26.General considerations for all models
For all rat models of surgically-induced OA it is recommended
that skeletally mature animals, 12 weeks of age or older, be used to
mimic the development of OA in humans as closely as possible.
Young, growing rats develop far less cartilage pathology (S. Glasson,
personal communication), presumably because of the higher level
of matrix synthesis in younger animals. For many studies, it is
optimal to collect serum, urine and synovial ﬂuid for biomarker
analysis. A mature growth plate is preferred, since the turnover of
this tissue contributes many collagen type II and aggrecan frag-
ments to the serum and urine pool. These considerations could
necessitate the use of much older rats, such as the 9-month-old
females used by Hoegh-Andersen et al.21. However, using such aged
rats for routine drug discovery studies is not practical and should be
reserved for follow-up biomarker studies where the proof-of
concept for disease modiﬁcation has been clearly established.
Various strains of rats are used, primarily Lewis, Sprague-Daw-
ley (SD) orWistar rats. While the use of SD rats is often described in
the literature, Lewis rats are preferred for the MMT and
ACLTþ pMMxmodels. In side-by-side comparisons of Lewis and SD
rats in the MMT model, for example, Lewis and SD rats responded
differently to the surgery (A. Bendele, unpublished results). Lesions
in the Lewis rats are uniformly more severe in the outer 1/3 of the
proximal tibia, progressing to less severe lesions in the middle and
inner thirds (Fig. 1), whereas the SD rats tend to have lesions of
equal or sometimes slightly greater severity in the middle 1/3 than
the outer 1/3 and generally develop larger osteophytes than the
Lewis rats. SD rats also have a tendency to develop spontaneous
cartilage cysts with aging [Fig. 7(A)]. Since it is becoming increas-
ingly popular to carry out OA studies of more than 3 weeks dura-
tion, the incidence and severity of these cysts in older SD rats make
this a less desirable species than Lewis rats for OA studies.
Variability in the severity of lesions within the same model
can occur when the surgery is performed by individuals with
non-uniform surgical skills, and this is true of all surgical models.
For example, the lesions observed in animals after an individual
performs the surgery for the ﬁrst time are usually quite severe;
these tend to decrease in severity as the surgeon gains experience.
The reason for this may lie in the extent towhich the joint capsule is
opened (as this would inﬂuence the level of instability in the joint),
the period of time the joint is open (potential for drying out), the
extent of bleeding (which may cause plasmin activation of MMPs
and synovitis), the amount of suture material left in the joint, and
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effects, animals among different treatment groups should be
randomized according to surgeon as well as to the order in which
they underwent the surgical procedure.
In our opinion, the best model of OA for testing therapeutic
interventions is one in which there is a mild-to-moderate rate of
progression with a sufﬁcient duration for the development of
robust lesions, thus allowing for differentiation among the treat-
ment groups. For example, we have observed in the rat MMTmodel
that while modest treatment efﬁcacy was observed at the 3-week
time point, a far more robust response was appreciated at a later
time point (3 months), when lesions of cartilage degenerationwere
more severe (A. Bendele and S. Glasson, unpublished results).
Scoring
Macroscopic staging
Gross evaluation of joints is generally not done for rat surgery
models since this would require dissection, which would alter the
spatial relationships among the tibia, femur and synovium.
Opening the joint also would prevent evaluation of ﬁbrous repair of
the joint capsule and changes in the synovium. Nevertheless,
macroscopic evaluation of cartilage surfaces is described for the
MMT, ACLTþ pMMx and ACLT models (Fig. 2).4,9,10,26 In unstained
tibial plateaus and femoral condyles, surface abrasion and ﬁbrotic
tissue are visible as surface roughness and osteophytes are opaque,
compared to the smooth, glassy appearance in unoperated joints or
sham controls. When the tibial plateaus and femoral condyles are
examined grossly after staining with Evan’s blue, only the cartilage
lesions stain blue and these areas can be quantiﬁed by histo-
morphometry. Greater contrast can be obtained with joints that are
stained before ﬁxation compared with those that are ﬁxed before
staining. For quantiﬁcation, the surfaces of tibial plateaus or
femoral condyles should be photographed followed by measure-
ment of the total surface area of the joint vs the area of lesion(s) to
allow calculation of the % surface area affected.
Microscopic scoring
Recommended methods for processing of joints: ﬁxation,
decalciﬁcation, embedding, sectioning and staining
Rat joints are most frequently ﬁxed in 10% formaldehyde for
about 3 days. Various protocols have been described for decalciﬁ-
cation. In our experience decalciﬁcation in Immunocal (Decal
Chemical Corporation, Tallman, NY) or 5% formic acid for 11e12
days or in 20% ethylenediaminetetraacetic acid (EDTA) for 14e21Fig. 2. Macroscopic features of Evan’s blue-stained tibial plateaus in the rat MMT mode
B. a rat that had undergone MMT 3 weeks before. Cartilage lesions are apparent on the MTdays works well for mature rats. Decalciﬁcation times need to be
adapted, depending on the age of the animals, with the longer time
interval used for older animals.
Frontal sectioning
The most frequently used method of embedding and sectioning
formicroscopic evaluation is frontal sectioning4,9,25,26. To accomplish
this, joints are cut into two approximately equal halves, an anterior
andaposteriorone, along themedial collateral ligament in the frontal
plane. This is aided by removing the patella and immobilizing the
jointbyholding it along thepatellar grooveandanterior surfaceof the
knee joint with blunt forceps in one hand and restraining the poste-
rior aspect with the other. This somewhat straightens the joint and
allows, after positioning the joint on a cutting board, for aligning the
cut through the middle of the arms of the forceps with a razor blade.
The two resulting tissue pieces (anterior and posterior half) are then
both embedded in a single parafﬁn block with the cut planes facing
down. The resulting histological sections will include both femoral
condyles, tibial plateaus and menisci, but will not include the troch-
lear groove or patella.
Three 4e8 mm sections should be cut from each parafﬁn block at
approximately 200 mm steps to obtain three sections from each half
(anterior and posterior) of the knee. If the contralateral knee is used
a control (e.g., as a staining controls for quantiﬁcation of PG loss) it is
sufﬁcient to prepare a single section. If frontal sections are done in
a consistent manner, 300e325 g rats will have a consistent width
across the MTP of approximately 2000 mm. It is important that this
measurement is consistent for subsequentmeasures of degradation
across that surface. Sectioning through the entire knee joint may be
requiredwhenamodel is beingnewlyestablished, inorder toensure
that the exact location and entire extent of the lesions are detected.
Coronal sectioning
For preparation of coronal sections7 (Gerwin and Gliem,
unpublished results), the intact ﬂexed joint is embedded in parafﬁn,
with the patella facing down. The most reproducible results are
achieved if the amount of ﬂexion in every knee joint studied is the
same, e.g., 120, which can be achieved by mounting the trimmed
knee joint on a plastic trianglewith a 120 angle forﬁxation. Coronal
sectioning of the parafﬁn-embedded, ﬂexed knee joint is started
from the anterior aspect of the leg at the patella and is continued
posteriorly through the femoral condyles. The knee joint is carefully
oriented using the shapes of the growth plates and menisci as
hallmarks to ensure that sections are coronal, i.e., all four condyles
are sectioned at the same depth. Preparation of sections at 200 mm
steps will yield a total of about 10e15 collection points, depending
on the age of the rats. If the model is well established, it may bel (image was taken from reference4). Tibial plateau from A. an unoperated rat, and
P as crescent-shaped, Evan’s blue-stained area (arrows).
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areas containing the lesions, similar to the technique for frontal
sections. For sectioning through the entire joint, coronal sectioning
is more time consuming than the previously-described frontal
sectioning method, because only one section is cut at a time. An
advantage of this technique, however, is that it offers the opportu-
nity to obtain optimally-oriented midcoronal sections by allowing
one to correct the angle of the parafﬁn block during sectioning.
Sagittal sectioning
The preparation of sagittal sections is described in the literature
and involves embedding the jointwith themedial (most commonly)
or lateral aspect down6,8,10. Sectioning is usually started at the
medial margin of the joint. Appleton et al.,10 for example, started
collection of sections at about 180 mm from the joint margin and
collected about 40 sections at 30 mmintervals across the entire joint.
The choice of sectioning method will be dependent on the loca-
tion of the lesion in a particularmodel. Sincemost instabilitymodels
have the most severe lesions on the central weight-bearing area of
the plateau or condyle, one may assume that measurement of the
maximal score or extent of these lesions will yield similar results in
sagittal vs frontal or coronary sections. However, to our knowledge,
a side-by-side comparison of frontal/coronal and sagittal sections to
ensure that this is correct has not been done. A disadvantage of the
sagittal sectioningmethod is that osteophytes, which are frequently
found in the medial compartment, are difﬁcult to detect and quan-
tify, since the sections are cut parallel, rather than perpendicular, to
the osteophyte. In addition, changes in synovial tissue e.g., synovial
inﬂammation, thickening or pannus formation, are not as easily
detectable in sagittal sections as in frontal or coronal sections.
Staining
The most frequently used staining methods are Toluidine blue,
Safranin O-Fast Green and Hematoxylin & Eosin (H&E). For the
recommended method of scoring (see below) it is important that
the stain is sensitive enough to clearly demarcate the tidemark,
which is the case for H&E and some methods of Toluidine blue
staining (see Supplemental Table I, for staining protocol). Since
Toluidine blue and Safranin O stains are relatively speciﬁc for
cartilage glycosaminoglycans and PGs, these stains can be used to
detect areas of PG loss in cartilage. Quantiﬁcation of cartilage PG
staining intensity in Toluidine blue and Safranin O-Fast Green
stained sections by histomorphometry is not recommended, even if
sections from the contralateral knee are used as staining controls,
since binding of both stains appears to be stoichiometric only
within a relatively limited range of PG content of the tissue27.
Scoring of sections
Most of the microscopic scoring systems described for rat OA
modelsusemodiﬁedMankin scores28,whichwereoriginallyadapted
for other species and include speciﬁc adaptations for rats; however,
very few of themodiﬁcations are described in detail4,26,29,30. Most of
these schemes restrict evaluation of OA to cartilage changes, while
a few include OA-related changes in bone and synovium. In some of
the recently published rat OA studies10,30 the OARSI score31 is used,
whichmultiplies the cartilage damage score by a factor to reﬂect the
extent of the tibial plateau that is involved.
For a general histological assessment of OA in rats, a modiﬁed
Mankin score, like the one described for guinea pigs in this issue,
may be sufﬁcient. The scoring system that we recommend,
however, has proven particularly useful for sensitive detection of
the effects of various treatments on the severity of OA. Our
recommendation for scoring of frontal sections, prepared as
described above, is provided below. Primary and supplemental
measures are indicated under each section.Histologic scoring is performed on the three most severely
affected sections. These are selected from either the anterior or
posterior sections of the knee from the three slides obtained per
knee joint at 200 mm intervals using the frontal sectioning method,
or from the three most severely affected consecutive sections (at
200 mm intervals) using the coronal sectioning method. The values
for each parameter (listed below) are then averaged across the
three scored sections per knee joint.
The scoring methods for the parameters listed below are
described for the MTP unless indicated otherwise. The decision
whether or not to evaluate the medial and lateral femoral condyles
and the lateral tibial plateau, as well, depends on the model. If the
model previously has been described and validated and the lesions
are most severe in the MTP, it may be sufﬁcient to restrict the
scoring to the MTP. If not, the entire joint should be evaluated to
determine the location of the most severe lesions.
#1 Cartilage matrix loss width. The progression of cartilage matrix
loss in the rat involves superﬁcial ﬁbrillation and loss of matrix
initially, followed bya deeperﬁbrillation/matrix loss through themid
zones and widening of the lesion, eventually resulting in full-thick-
ness lossofmatrix to the tidemark in focal or locallyextensive regions.
In order to assess these progressive changes in an objective manner,
the width of the area of collagen matrix loss is measured along the
surface (0% depth), as well as at the level of themidzone (50% depth)
and tidemark (100% depth; Fig. 3). Only areas of complete cartilage
matrix loss are measured; areas of degenerated cartilage affected by
only PG or chondrocyte loss are not evaluated. Themeasurement can
beperformedbyeitheruseof amicrometerdirectly in themicroscope
or by capturing an image of the slide and takingmeasurements using
a basic image analysis program. Measures are expressed in microns.
Any ﬂoating debris in the lesion is ignored.
We recommend to measure in the following order:
 Surface (0% depth): width of any cartilage matrix loss along the
projected cartilage surface, where the cartilage on either side
has intact superﬁcial cartilage.
 Tidemark (100% depth): width of cartilage matrix loss at the
level of the tidemark.
 Midzone (50% depth): width of cartilage matrix loss at the
midpoint of the cartilage thickness (between surface and
tidemark).#2 Cartilage degeneration score. This score is anevaluationof overall
cartilage pathology and includes the important pathology parame-
ters of collagen matrix ﬁbrillation/loss and chondrocyte death/loss
with chondrocyte loss being the primary determinant of the score.
PG loss will be present in these areas of matrix and/or chondrocyte
loss and, therefore, is also included. Areas of cartilage in which PG
loss is present, butwhich contain no evidence of chondrocyte death,
are excluded when evaluating this parameter because these are
covered in the total width measure (#3 below). For the cartilage
degeneration score, the MTP is divided into three zones in order to
evaluate pathology of different load-bearing areas (Fig. 4). Cartilage
degeneration in each zone is scored ‘none’ to ‘severe’ (numerical
values 0e5) using the criteria described in Table II.
A micrometer is placed over the entirewidth of the load-bearing
medial tibial cartilage plateau (from the edge of the osteophyte, or
the junction of weight-bearing cartilage with the marginal zone,
across the load-bearing surface) to enable dividing the entire width
into three regions of equal width, an outer zone 1 (at the medial
edge of joint), a central zone 2 and an inner zone 3 (adjacent to the
central cruciate ligaments). The original surface of the tissue must
be estimated. Then the % area of each zone that contains cartilage
Fig. 3. #1Cartilagematrix losswidth.Histological sections of theMFC and theMTPof unoperated rats (A.) and ratswithOA lesions at 1 (B.), 3 (C.) and13 (D.)weeks followingMMT. For
evaluation, the widths of collagen matrix loss are measured in relation to the depth of full-thickness non-calciﬁed cartilage matrix. Widths may be measured with a computerized
imaging system, a reticule, or onphotographs, as long as accurate calibration/micron bar references are utilized. Thesewidths can be tabulated to provide avisual reﬂection of the lesion
architecture and comparisons can be made for these continuous variables in multiple statistical tests. In general, comparisons between the widths at 50% depth of matrix loss across
treatment groups and time points are the most sensitive of all of the depth measures at reﬂecting changes. The width of lesions is measured at 0%, 50% and 100% depths.exhibiting loss of chondrocytes (50% or greater loss of normal
cellularity) or loss of matrix is estimated (or measured with an
image analysis program) and a score is assigned to that zone based
on that percentage.
A 3-zone-sum for cartilage degeneration is also calculated by
adding the values obtained for each zone. The maximum 3-zone-
sum for the medial tibia is 15.
The same process is applied to evaluation of the femoral
condyles and the lateral tibial plateau, if desired, with the exception
that lesions in these sites are not analyzed based on zones since
they are not generally distributed over the surface in a zonal
pattern. The total width of the load-bearing surface (approximately
2000 mm for femur) should be determined and the same criteria
applied as described for evaluating general pathology of tibia to the
most severely affected 1/3, 2/3 or 3/3. For example, if 1/3 of the total
area (lesion may be in the center of the plateau covering about
667 mm) has minimal degeneration (5e10% of total area has loss of
chondrocytes and/or matrix), a grade of 1 is assigned. If that
minimal degeneration extends over the entire surface (3/3) then
the grade is 3. If the entire femoral cartilage is absent as a result of
severe diffuse degeneration, then the grade is 15.
#3 Total cartilage degeneration width. The total width of the area of
articular cartilage affected by any type of degenerative changeTable II





1 Minimal degeneration; 5e10% of the total projected
cartilage area affected by matrix or chondrocyte loss
2 Mild degeneration; 11e25% affected
3 Moderate degeneration; 26e50% affected
4 Marked degeneration; 51e75% affected
5 Severe degeneration; greater than 75% affected(matrixﬁbrillation/loss, PG losswith orwithout chondrocyte death)
is measured in micrometers. This measurement takes into account
foci of minor change (PG loss only), especially in zone 3, that are
excluded from the cartilage degeneration score (#2 above). The
measurement extends from the point on the cartilage surfacewhere
degeneration of the underlying cartilage begins in zone 1, across the
areaof cartilagedegeneration to thepointwhere the tangential layer
and underlying cartilage appear histologically normal (Fig. 5). All
areas of abnormal matrix across the surface are measured. If there
are interveningareasofnormal cartilage, theyarenot included in the
measurement. In general, thewidth of load-bearing cartilage across
the tibia is veryconsistent (2000 mmina300 g rat) thus allowing this
parameter to be expressed as an absolute value rather than %.
However, if sectioning is not consistent and totalwidths arevariable,
this parameter needs to be expressed as % of total width.
#4 Signiﬁcant cartilage degeneration width. This parameter is
a measurement of the width of the tibial cartilage in which 50% or
greater of the thickness (from surface to tidemark) is seriously
compromised (Fig. 5). A cartilage area is considered to be seriously
compromised when 50% of chondrocytes are absent or necrotic, with
or without collagen matrix loss; therefore, this measurement corre-
lates with the cartilage degeneration score (#2 above). In general,
chondrocyte and PG loss are more extensive than the collagen matrix
loss and often extend to at least 50% or greater of the cartilage depth in
zones 1 and 2. Signiﬁcant cartilage degeneration width is measured
andmay be expressed as an absolute value or as percent of total tibial
cartilage width. Measurement of this parameter is an easy, rapid
method for identifying effects of treatments on more severe cartilage
changes, as it only includes moderate to severe degeneration and
excludes minimal to mild changes (covered in other measures).
#5 Zonal depth ratio of lesions (Supplemental). This is a measure-
ment of the depth of cartilage degeneration (e.g., including areas of
Fig. 4. #2 Cartilage degeneration score. Histological sections of the medial joint compartment of a rat with OA lesions following MMT. For evaluation, the tibial plateau is divided
into three zones of equal width (marked by red vertical lines), with zone 1 (Z1) on the outside (medial edge of joint) and zone 3 (Z3) on the inside (adjacent to the central cruciate
ligaments). The area of non-viable cartilage (signiﬁcant chondrocyte loss but with collagen retention) is indicated by yellow tracing; the entire projected cartilage area is delineated
by green tracing. A. Nearly all (99%) of the cartilage matrix has been lost or severely damaged in Z1 (grade of 5), 75% in Z2 (grade of 4), and 13% in Z3 (grade of 2). B. In this example
of less severe general cartilage degeneration, 61% of the cartilage matrix has been lost or severely damaged in Z1 (grade of 4), 49% in Z2 (grade of 3), and there is no loss of cartilage
matrix in Z3 (grade of 0).
Fig. 5. #3 and #4 Total and signiﬁcant cartilage degeneration width. #3. The total cartilage degeneration width (black horizontal line) represents the total extent of the tibial
plateau affected by any type of degeneration (matrix ﬁbrillation/loss, PG loss with or without chondrocyte death). The measurement is taken at the projected cartilage surface from
the outer edge of the tibial plateau, adjacent to the osteophyte (outer red line), to the point at which the cartilage is normal (inner red line). #4. The signiﬁcant cartilage
degeneration width (yellow horizontal line) represents the width of tibial cartilage in which 50% or more of the original cartilage thickness is seriously compromised by collagen
matrix loss or loss of 50% of chondrocytes (and concurrent PG) loss. A. Example of tibial plateau with large total and signiﬁcant tibial cartilage degeneration width and B. example
with smaller cartilage degeneration width.
Fig. 6. #5 Zonal depth ratio of lesions. The lesion depth ratio is calculated by dividing the depth of the lesion (yellow line) by the thickness of the cartilage from projected articular
surface to tidemark (black vertical line). These measurements are taken at the midpoint of each zone using an ocular micrometer. If care is taken to consistently measure the total
depth (cartilage thickness) in the same location in each section, this parameter can also be used effectively with anabolic treatments to document cartilage thickening and increased
matrix. Examples of A. high and B. low depth ratio of lesion.
N. Gerwin et al. / Osteoarthritis and Cartilage 18 (2010) S24eS34S30
Fig. 7. #6 Osteophyte score. The largest osteophyte in the section (typically in the tibia) is measured from base to edge at the thickest point (red line) and then given a score based
on that measurement. A. Large osteophyte. This section is from a SD rat after MMT, whereas all other sections shown here are from Lewis rats. Cartilage cysts (arrow) are common in
aged SD rats and rarely seen in Lewis rats. B. Small osteophyte.
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collagenousmatrix and no ﬁbrillation) that is taken at the midpoint
in each of the three zones across the tibial surface. The lesion depth
ratio is calculated by dividing the micrometer depth of the area of
degeneration by the thickness of the cartilage (both in microme-
ters), from projected cartilage surface to tidemark (Fig. 6).
#6 Osteophytes. The largest osteophyte in each section is measured
(from the deepest point of its base at the chondro-osseous junction
to the surface of the overlying cartilage at its thickest point) using
an ocular micrometer (Fig. 7). Based on that measurement a grade
is assigned according to Table III. The actual osteophyte measure-
ment is also recorded.
#7 Calciﬁed cartilage and subchondral bone damage score
(Supplemental). This parameter is used to quantify effects of agentsFig. 8. #7 Calciﬁed cartilage and subchondral bone damage. A. Grade 0 e normal calciﬁed
cartilage in the central load-bearing area of the joint (red arrow). B. Grade 1 e increased bas
Increased thickening of subchondral bone subjacent to the area of greatest cartilage lesion se
the tidemark (red arrow), minimal to mild focal fragmentation of calciﬁed cartilage of the tid
lesion. D. Grade 3 e increased basophilia at the tidemark (red arrow), mild to marked multifo
4 of total area. Areas of marrow chondrogenesis are evident. E. Grade 4 e increased basoph
and marrow mesenchymal changes involving up to 3/4 of the area. Articular cartilage has co
under the area of collapse are a result of chondrogenesis in the bone marrow. F. Grade 5 em
of cartilage and some chondrogenesis in the marrow (red arrows). Marrow mesenchymal
Articular cartilage has collapsed into the epiphysis to a depth of greater than 250 mm fromon OA-associated changes in subchondral bone and calciﬁed
cartilage (Fig. 8; Table IV). The most severe lesion is scored in each
section. It is usually located subjacent to the articular cartilage
lesion of greatest severity.#8 Synovial reaction (Supplemental). If the synovial membrane is
abnormal, it is described and characterized with respect to
inﬂammation type, extent, and severity. The score given in Table V
characterizes surgery-induced inﬂammation based on increased
numbers of synovial lining cell layers, proliferation of subsynovial
tissue, and inﬁltration of inﬂammatory cells.#9 Medial joint capsule repair. In addition, measurements may be
made of the thickness of medial/collateral joint capsule repair in
a non-tangential area of the section. (Fig. 9)cartilage and subchondral bone, however, slight increase in basophilia of the calciﬁed
ophilia at the tidemark (red arrow) and minimal focal marrow changes (black arrows).
verity is observed in grade 1 and all higher grades. C. Grade 2 e increased basophilia at
emark, and mesenchymal change in marrow involving 1/4 of subchondral region under
cal fragmentation of calciﬁed cartilage, and mesenchymal change in marrow of up to 3/
ilia at the tidemark (red arrows), marked to severe fragmentation of calciﬁed cartilage,
llapsed into the epiphysis (see deﬁnite depression in surface cartilage). Basophilic areas
arked to severe fragmentation of calciﬁed cartilage and subchondral bone with collapse
changes involve up to 3/4 of the area and a large bone cyst (black arrow) is present.
the tidemark with associated bone resorption.
Table V




0 No changes (1e2 layers of synovial lining cells)
1 Increased number of lining cell layers
(3e4 layers) or
 slight proliferation of subsynovial tissue.
2  Increased number of lining cell layers
(3e4 layers) and/or
 proliferation of subsynovial tissue.
3  Increased number of lining cell layers
(>4 layers) and/or
 proliferation of subsynovial tissue and
 inﬁltration of few inﬂammatory cells.
4  Increased number of lining cell layers
(>4 layers) and/or
 proliferation of subsynovial tissue,





Osteophytes 0 Marginal zone proliferative changes <200 mm
1 Small 200e299 mm
2 Moderate 300e399 mm
3 Large 400e499 mm
4 Very large 500 mm
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may be measured medially and laterally (two measures/joint),
midway between the center of the physis and the medial (medial
measurement) or lateral (lateral measurement) margin if an over-
view of the sections suggests that differences in growth plate width
are present. It is recommended to only measure growth plate
thickness in sections of tibia, as these sections are more likely than
those of the femur to be taken in a plane perpendicular to the
growth plate in frontal sections.
Data analysis
If three sections per joint are analyzed, the mean standard
error (SE) for each parameter or measurement is determined in
order to obtain a total joint score. Statistical analysis is performed
using ANOVA analysis. Measured parameters, such as cartilageTable IV






1  Increased basophilia at tidemark,
 no fragmentation of tidemark,
 no marrow changes or, if present,
minimal and focal,
 increased thickening of subchondral
bone subjacent to the area of greatest
articular cartilage lesion severity.
2  Increased basophilia at tidemark,
 minimal to mild focal fragmentation of
calciﬁed cartilage of tidemark,
 mesenchymal change in marrow
(ﬁbroblastic cells) involving about 1/4
of subchondral region under lesion,
 increased thickening of subchondral
bone subjacent to the area of greatest
articular cartilage lesion severity.
3  Increased basophilia at tidemark,
 mild to marked fragmentation
(multiple larger areas) of calciﬁed
cartilage/subchondral bone loss,
 mesenchymal change in marrow in up
to 3/4 of total area,
 areas of marrow chondrogenesis may
be evident but no major collapse of
articular cartilage into epiphyseal bone
(deﬁnite depression in surface).
4  Increased basophilia at tidemark,
 marked to severe fragmentation of
calciﬁed cartilage,
 marrow mesenchymal change involves
up to 3/4 of area,
 articular cartilage has collapsed into the
epiphysis to a depth of 250 mm or less
from tidemark (see deﬁnite depression
in surface cartilage).
5  Increased basophilia at tidemark,
 marked to severe fragmentation of
calciﬁed cartilage,
 marrow mesenchymal change involves
up to 3/4 of area,
 articular cartilage has collapsed into the
epiphysis to a depth of greater than
250 mm from tidemark.degeneration width, are analyzed using parametric ANOVA
methods. When several treatment groups are compared, multiple
comparison procedures such as Bonferroni or Tukey correction are
used. Dunnett’s test is applied when only comparisons to vehicle
are of interest. Scored parameters are analyzed using a Krus-
kaleWallis test with Dunn’s post-test.
Reliability study
A set of photomicrographs of 18 rat knee joint histological
sections was graded by 11 individuals using the recommended
scoring scheme. The intra-class correlation coefﬁcients (ICCs)
depicting the inter-rater reliability of grading the features of the
scoring system are shown in Table VI. The “expert” category
encompasses graders who either had extensive experience with
scoring OA lesions or received training with Alison Bendele. The
“novice” category included all other graders. Results obtained by
Alison Bendele (cartilage parameters) and Sonya Glasson (cartilage
matrix loss widths), are considered to be the most accurate and
were included in both groups in order to evaluate variability rela-
tive to the actual scores and measurements.
Correlation was very high in both the novice and expert
groups, with the exception of two parameters. In the ﬁrst case,
which included cartilage degeneration scores in zone 3 of the
medial tibia, ICC results were likely magniﬁed due to theTable VI
Reliability study. ICCs* depicting the inter-rater reliability within expert and novice
groups for the grading of 18 histological sections each
Parameter Histological feature Experts (n¼ 4) Novices (n¼ 8)
1 Cartilage matrix loss width e
0% Depth
0.94 (0.88, 0.97) 0.85 (0.74, 0.93)
Cartilage matrix loss width e
100% Depth
0.99 (0.98, 1) 0.97 (0.94, 0.99)
Cartilage matrix loss width e
50% Depth
0.95 (0.9, 0.98) 0.93 (0.87, 0.97)
2 3-Zone Tibial CDSy total 0.92 (0.85, 0.97) 0.88 (0.79, 0.94)
Zone 1 Tibial CDSy 0.90 (0.81, 0.96) 0.86 (0.76, 0.94)
Zone 2 Tibial CDSy 0.92 (0.85, 0.97) 0.90 (0.82, 0.95)
Zone 3 Tibial CDSy 0.67 (0.46, 0.84) 0.44 (0.26, 0.66)
Femoral CDSy 0.92 (0.85, 0.97) 0.88 (0.79, 0.94)
3 Total tibial cartilage degeneration
width
0.62 (0.4, 0.81) 0.50 (0.32, 0.71)
4 Signiﬁcant tibial cartilage
degeneration width
0.89 (0.79, 0.95) 0.77 (0.63, 0.89)
5 Osteophyte measurement 0.95 (0.9, 0.98) 0.97 (0.94, 0.99)
Osteophyte score 0.91 (0.82, 0.96) 0.95 (0.91, 0.98)
Total joint score w/o femur 0.93 (0.86, 0.97) 0.92 (0.86, 0.96)
Total joint score 0.93 (0.86, 0.97) 0.92 (0.86, 0.96)
* 95% Conﬁdence intervals for each ICC are listed in parenthesis.
y CDS¼ cartilage degeneration score.
Fig. 9. #9 Medial joint capsule repair. A. Normal medial joint capsule (no surgery). B. Medial joint capsule from a vehicle-treated animal 3 weeks after MMT surgery. C. Medial
joint capsule from an animal treated with compound that enhanced repair 3 weeks after MMT surgery. D.Medial joint capsule from an animal treated with compound that inhibited
repair 3 weeks after MMT surgery. Thickness of the medial joint capsule is measured as indicated by the black bar.
N. Gerwin et al. / Osteoarthritis and Cartilage 18 (2010) S24eS34 S33extremely low scores and lack of variation typically seen in this
region. The other parameter with low correlation, which was total
tibial cartilage degeneration width, involves more subtle changes
in the cartilage, which may not have been as evident in the
photomicrographs as they would be when viewed directly in the
microscope.
Discussion
This work is the result of the efforts of an experienced group of
rat OA investigators to develop and describe a reproducible and
accurate scheme for the histological evaluation of lesions of OA in
this species. The validation study revealed that this scheme, while
not as simple to use as some other modiﬁed Mankin scores, may be
used reproducibly by individuals with variable experience in the
histopathologic evaluation of OA. In addition, this scheme has been
used effectively in multiple studies for efﬁcacy evaluation of
disease-modifying OA treatments in experimentally-induced OA in
rats5,23,29.
Disclosures
Sub-coordinator Nicole Gerwin is an employee of and holds
stock in Novartis.
Sub-coordinator Alison Bendele is Director of BolderBioPATH
Inc., a contract research laboratory for preclinical studies in
arthritis.
Committee member Sonya Glasson is an employee of and holds
stock in Pﬁzer.
Committee member Cathy S. Carlson is employed at the College
of Veterinary Medicine, University of Minnesota.
Conﬂict of interest
No author has any conﬂict of interest related to this work.Acknowledgements
We thank Ben Kriederman (Histotox), Brian Omura (Bolder-
BioPATH), Connie Kilwinski (Centocor), Julio Tejada (Pﬁzer),
Margaret McNulty (Carlson laboratory), Nicole Schmitz (Aigner
laboratory), Phil Bendele (BolderBioPATH), and Steve Settle (Pﬁzer)
for participating in the reliability study. No external sources of
funding were provided for this work except that the printing costs
were supported by an unrestricted educational grant to OARSI by
Bayer, Expanscience, Genzyme, Lilly, MerckSerono, Novartis, Pﬁzer,
SanoﬁAventis, and Servier. The work performed was not inﬂuenced
at any stage by the support provided.Supplementary data
Supplementary data associated with this article can be found in
the online version at doi:10.1016/j.joca.2010.05.030.References
1. Gyarmati J, Foldes I, Kern M, Kiss I. Morphological studies on
the articular cartilage of old rats. Acta Morphol Hung 1987;35
(3e4):111e24.
2. Smale G, Bendele A, Horton WRJ. Comparison of age-associ-
ated degeneration of articular cartilage in Wistar and Fischer
344 rats. Lab Anim Sci 1995;45(2):191e4.
3. Bendele AM. Animal models of osteoarthritis. J Musculoskelet
Neuronal Interact 2001;1(4):363e76.
4. Janusz MJ, Bendele AM, Brown KK, Taiwo YO, Hsieh L,
Heitmeyer SA. Induction of osteoarthritis in the rat by surgical
tear of the meniscus: inhibition of joint damage by a matrix
metalloproteinase inhibitor. Osteoarthritis and Cartilage
2002;10(10):785e91.
N. Gerwin et al. / Osteoarthritis and Cartilage 18 (2010) S24eS34S345. Moore EE, Bendele AM, Thompson DL, Littau A, Waggie KS,
Reardon B, et al. Fibroblast growth factor-18 stimulates chon-
drogenesis and cartilage repair in a rat model of injury-induced
osteoarthritis. Osteoarthritis and Cartilage 2005;13(7):623e31.
6. Williams JM, Felten DL, Peterson RG, O’Connor BL. Effects of
surgically induced instability on rat knee articular cartilage.
J Anat 1982;134(Pt 1):103e9.
7. Stoop R, Buma P, van der Kraan PM, Hollander AP,
Billinghurst RC, Poole AR, et al. Differences in type II collagen
degradation between peripheral and central cartilage of rat
stiﬂe joints after cranial cruciate ligament transection. Arthritis
Rheum 2000;43(9):2121e31.
8. Karahan S, Kincaid SA, Kammermann JR, Wright JC. Evaluation
of the rat stiﬂe joint after transection of the cranial cruciate
ligament and partial medial meniscectomy. Comp Med
2001;51(6):504e12.
9. Hayami T, Pickarski M, Zhuo Y, Wesolowski GA, Rodan GA,
Duong LT. Characterization of articular cartilage and sub-
chondral bone changes in the rat anterior cruciate ligament
transection and meniscectomized models of osteoarthritis.
Bone 2006;38(2):234e43.
10. Appleton CT, McErlain DD, Pitelka V, Schwartz N, Bernier SM,
Henry JL, et al. Forced mobilization accelerates pathogenesis:
characterization of a pre-clinical surgical model of osteoar-
thritis. Arthritis Res Ther 2007;9(1):R13.
11. Lozoya KA, Flores JB. A novel rat osteoarthrosis model to assess
apoptosis and matrix degradation. Pathol Res Pract 2000;196
(11):729e45.
12. Galois L, Etienne S, Grossin L, Watrin-Pinzano A, Cournil-
Henrionnet C, Loeuille D, et al. Dose-response relationship for
exercise on severity of experimental osteoarthritis in rats:
a pilot study. Osteoarthritis and Cartilage 2004;12(10):779e86.
13. Kalbhen DA. Chemical model of osteoarthritisea pharmaco-
logical evaluation. J Rheumatol 1987;14(Suppl 14):130e131.
14. Guingamp C, Gegout-Pottie P, Philippe L, Terlain B, Netter P,
Gillet P. Mono-iodoacetate-induced experimental osteoar-
thritis: a dose-response study of loss of mobility, morphology,
and biochemistry. Arthritis Rheum 1997;40(9):1670e9.
15. Guzman RE, Evans MG, Bove S, Morenko B, Kilgore K. Mono-
iodoacetate-induced histologic changes in subchondral bone
and articular cartilage of rat femorotibial joints: an animal
model of osteoarthritis. Toxicol Pathol 2003;31(6):619e24.
16. JanuszMJ, Little CB, King LE, Hookﬁn EB, BrownKK, Heitmeyer SA,
et al. Detection of aggrecanase- and MMP-generated catabolic
neoepitopes in the rat iodoacetate model of cartilage degenera-
tion. Osteoarthritis and Cartilage 2004;12(9):720e8.
17. Gelse K, von der Mark K, Aigner T, Park J, Schneider H. Articular
cartilage repair by gene therapy using growth factor-producing
mesenchymal cells. Arthritis Rheum 2003;48(2):430e41.
18. Ikeda T, Kubo T, Nakanishi T, Arai Y, Kobayashi K, Mazda O, et al.
Ex vivo gene delivery using an adenovirus vector in treatment
for cartilage defects. J Rheumatol 2000;27(4):990e6.
19. Kuroda R, Usas A, Kubo S, Corsi K, Peng H, Rose T, et al. Cartilage
repair using bonemorphogenetic protein 4 andmuscle-derived
stem cells. Arthritis Rheum 2006;54(2):433e42.
20. Nishida T, Kubota S, Kojima S, Kuboki T, Nakao K, Kushibiki T,
et al. Regeneration of defects in articular cartilage in rat knee
joints by CCN2 (Connective Tissue Growth Factor). J Bone
Miner Res 2004;19(8):1308e19.
21. Hoegh-Andersen P, Tanko L, Andersen T, Lundberg C, Mo J,
Heegaard AM, et al. Ovariectomized rats as a model of post-
menopausal osteoarthritis: validation and application.
Arthritis Res Ther 2004;6(2):R169e80.
22. Ekenstedt KJ, Sonntag WE, Loeser RF, Lindgren BR, Carlson CS.
Effects of chronic growth hormone and insulin-like growthfactor 1 deﬁciency on osteoarthritis severity in rat knee joints.
Arthritis Rheum 2006;54(12):3850e8.
23. Baragi VM, Becher G, Bendele AM, Biesinger R, Bluhm H, Boer J,
et al. A new class of potent matrix metalloproteinase 13
inhibitors for potential treatment of osteoarthritis: evidence of
histologic and clinical efﬁcacy without musculoskeletal
toxicity in rat models. Arthritis Rheum 2009;60(7):2008e18.
24. Fernihough J, Gentry C, Malcangio M, Fox A, Rediske J, Pellas T,
et al. Pain related behaviour in two models of osteoarthritis in
the rat knee. Pain 2004;112(1e2):83e93.
25. Bove SE, Laemont KD, Brooker RM, Osborn MN, Sanchez BM,
Guzman RE, et al. Surgically induced osteoarthritis in the rat
results in the development of both osteoarthritis-like joint
pain and secondary hyperalgesia. Osteoarthritis and Cartilage
2006;14(10):1041e8.
26. Hayami T, Pickarski M, Wesolowski GA, McLane J, Bone A,
Destefano J, et al. The role of subchondral bone remodeling in
osteoarthritis: reduction of cartilage degeneration and
prevention of osteophyte formation by alendronate in the rat
anterior cruciate ligament transection model. Arthritis Rheum
2004;50(4):1193e206.
27. Hyllested JL, Veje K, Ostergaard K. Histochemical studies of the
extracellular matrix of human articular cartilageea review.
Osteoarthritis and Cartilage 2002;10(5):333e43.
28. Mankin HJ, Dorfman HA, Lippiello L, Zarins A. Biochemical and
metabolic abnormalities in articular cartilage from osteo-arthritic
human hips: II. Correlation of morphology with biochemical and
metabolic data. J Bone Joint Surg Am 1971;53(3):523e37.
29. Flannery C, Zollner R, Corcoran C, Jones A, Root A, Rivera-
Bermúdez M, et al. Prevention of cartilage degeneration in
a rat model of osteoarthritis by intraarticular treatment with
recombinant lubricin. Arthritis Rheum 2009;60(3):840e7.
30. Yorimitsu M, Nishida K, Shimizu A, Doi H, Miyazawa S,
Komiyama T, et al. Intra-articular injection of interleukin-4
decreases nitric oxide production by chondrocytes and
ameliorates subsequent destruction of cartilage in instability-
induced osteoarthritis in rat knee joints. Osteoarthritis and
Cartilage 2008;16(7):764e71.
31. Pritzker KPH, Gay S, Jimenez SA, Ostergaard K, Pelletier JP,
Revell PA, et al. Osteoarthritis cartilage histopathology: grading
and staging. Osteoarthritis and Cartilage 2006;14(1):13e29.
32. Wancket LM, Baragi V, Bove S, Kilgore K, Korytko PJ,
Guzman RE. Anatomical localization of cartilage degradation
markers in a surgically induced rat osteoarthritis Model.
Toxicol Pathol 2005;33(4):484e9.
33. Glasson S, Bendele AM, Sum P-E, Tam S, Tajeda J, Rivera-
Bermúdez M, et al. Selective aggrecanase inhibition is disease
modifying and pain alleviating in a rat meniscal tear model of
osteoarthritis. Osteoarthritis and Cartilage 2009;17(Suppl.1);
S56. Ref Type: Abstract.
34. Jean YH, Wen ZH, Chang YC, Hsieh SP, Tang CC, Wang YH,
et al. Intra-articular injection of the cyclooxygenase-2 inhib-
itor parecoxib attenuates osteoarthritis progression in ante-
rior cruciate ligament-transected knee in rats: role of
excitatory amino acids. Osteoarthritis and Cartilage 2007;15
(6):638e45.
35. Lin YS, Huang MH, Chai CY. Effects of helium-neon laser on the
mucopolysaccharide induction in experimental osteoarthritic
cartilage. Osteoarthritis and Cartilage 2006;14(4):377e83.
36. Yeh T, Wen Z, Lee H, Lee C, Yang Z, Jean Y, et al. Intra-articular
injection of collagenase induced experimental osteoarthritis of
the lumbar facet joint in rats. Eur Spine J 2008;17(5):734e42.
37. Salo PT, Hogervorst T, Seerattan R, Rucker D, Bray RC.
Selective joint denervation promotes knee osteoarthritis in
the aging rat. J Ortho Res 2002;20(6):1256e64.
